GlassScriptPhysician profile
Mazyar Malakouti
NPI 1962845305
$41,937.33
in general payments reported to CMS, 2019-2025
39 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $154 · 2021: $462 · 2022: $1,297 · 2023: $1,710 · 2024: $9,571 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $7,250 · Food and Beverage: $5,991 · Travel and Lodging: $3,603 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,633.86 |
| Consulting Fee | $7,250.00 |
| Food and Beverage | $5,991.47 |
| Travel and Lodging | $3,602.82 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $21,532.30 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $8,023.64 | 2024-2025 | Omvoh |
| Eli Lilly and Company | $5,497.34 | 2024 | Omvoh |
| Abbvie INC. | $1,719.11 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $1,163.68 | 2019-2025 | Tremfya, Stelara, Remicade |
| Boston Scientific Corporation | $524.04 | 2022-2024 | Axios, Exalt Model D |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.78 | 2019-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $284.60 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $277.83 | 2022-2023 | Ocaliva |
| Ethicon US, LLC | $261.30 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $239.16 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $229.09 | 2022-2025 | |
| Genzyme Corporation | $153.44 | 2023-2025 | |
| Qol Medical, LLC | $149.09 | 2022-2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $139.00 | 2024-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $129.76 | 2022-2024 | Sutab, Suflave |
| Shire North American Group INC | $122.60 | 2019 | |
| Steris Corporation | $121.27 | 2020 | |
| Merck Sharp & Dohme LLC | $120.97 | 2022-2023 | Dificid |
| Novo Nordisk INC | $117.92 | 2023 | Wegovy |
| Ferring Pharmaceuticals INC. | $115.03 | 2022-2025 | Rebyota |
| Celgene Corporation | $107.53 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $75.25 | 2024-2025 | Iqirvo |
| Organon LLC | $61.43 | 2022-2024 | Renflexis |
| Covidien LP | $53.44 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $49.10 | 2025 | Solar Compact |
| Daiichi Sankyo INC. | $47.96 | 2022-2023 | Injectafer |
| Ardelyx, INC. | $35.69 | 2023-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $31.96 | 2023-2024 | |
| Evoke Pharma, INC. | $26.65 | 2022-2023 | Gimoti |
| Madrigal Pharmaceuticals | $24.46 | 2024 | Resmetirom |
| Regeneron Healthcare Solutions, INC. | $23.78 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $22.33 | 2024 | Idacio |
| Amgen INC. | $22.27 | 2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $21.09 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.89 | 2023 | Linzess |
| Enterra Medical, INC. | $15.75 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.80 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,124.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazyar Malakouti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.